41 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18720427 | ORCHESTRATED PERSONALIZED THERAPY SYSTEMS AND METHODS | GEDRA, OLIVIA ROSE | 3681 | Final Rejection | Jun 14, 2024 |
| 18427000 | MANUFACTURING METHODS FOR PRODUCING ANTI-IL12/IL23 ANTIBODY COMPOSITIONS | CHEONG, CHEOM-GIL | 1645 | Final Rejection | Jan 30, 2024 |
| 18553272 | DRUG MATERIAL INTERACTIONS USING QUARTZ CRYSTAL MICROBALANCE SENSORS | DO, AN H | 2853 | Non-Final OA | Sep 29, 2023 |
| 18552504 | ANTI-TAU ANTIBODIES AND USES THEREOF | XIAO, YAN | 1642 | Non-Final OA | Sep 26, 2023 |
| 18284209 | HUMANIZED ANTIBODIES AGAINST PAIRED HELICAL FILAMENT TAU AND USES THEREOF | FAUST, AMBER KATHLEEN | 1643 | Non-Final OA | Sep 26, 2023 |
| 18549665 | USES OF CD79B ANTIBODIES FOR AUTOIMMUNE THERAPEUTIC APPLICATIONS | HADDAD, MAHER M | 1641 | Non-Final OA | Sep 08, 2023 |
| 18344973 | MATERIALS AND METHODS FOR BIOENGINEERED IPSC POPULATIONS | CANDELARIA, JULIANA IRENE | 1634 | Non-Final OA | Jun 30, 2023 |
| 18199007 | Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody | LOCKARD, JON MCCLELLAND | 1647 | Non-Final OA | May 18, 2023 |
| 18143749 | Use of Anti-EGFR/Anti-Met Antibody to Treat Liver Cancer | MOSELEY II, NELSON B | 1642 | Non-Final OA | May 05, 2023 |
| 18300248 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and Dexamethasone | SULLIVAN, DENNIS JOHN | 1642 | Final Rejection | Apr 13, 2023 |
| 18300183 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone | SULLIVAN, DENNIS JOHN | 1642 | Final Rejection | Apr 13, 2023 |
| 18128310 | Method of Treating Psoriasis with IL-23 Specific Antibody | ABBAS, SYED JARAR | 1674 | Non-Final OA | Mar 30, 2023 |
| 18175345 | Methods of Treating High Risk Multiple Myeloma | SANG, HONG | 1646 | Non-Final OA | Feb 27, 2023 |
| 18166878 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | JIANG, DONG | 1674 | Non-Final OA | Feb 09, 2023 |
| 18106531 | Methods for Reducing Infusion-Related Reactions in Patients Treated with EGFR/Met Bispecific Antibodies | REDDIG, PETER J | 1646 | Final Rejection | Feb 07, 2023 |
| 18006334 | FLUID FILTRATION SYSTEM | BEISNER, WILLIAM H | 1799 | Non-Final OA | Jan 20, 2023 |
| 18080634 | PROSTATE CANCER VACCINES AND USES THEREOF | BARRERA, IMMACULADA | 1671 | Non-Final OA | Dec 13, 2022 |
| 18080639 | VACCINES BASED ON MUTANT CALR AND JAK2 AND THEIR USES | BARRERA, IMMACULADA | 1671 | Non-Final OA | Dec 13, 2022 |
| 18009135 | CONTROLLED RELEASE OF SELF-EMBEDDING PARTICLES FOR LOCALIZED DRUG DELIVERY | KIM, DANIELLE A | 1613 | Final Rejection | Dec 08, 2022 |
| 17992369 | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody | HOWARD, ZACHARY C | 1674 | Non-Final OA | Nov 22, 2022 |
| 17980149 | Corticosteriod Reduction in Treatment with Anti-CD38 Antibody | HADDAD, MAHER M | 1641 | Final Rejection | Nov 03, 2022 |
| 18052172 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF GPRC5DXCD3 BISPECIFIC ANTIBODIES | GUSTILO, ESTELLA M | 1646 | Non-Final OA | Nov 02, 2022 |
| 17918140 | SYSTEMS, MATERIALS, AND METHODS FOR REVERSED-PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (RP-HPLC) IDENTIFICATION OF MULTI-SPECIFIC MOLECULES | BERKELEY, EMILY R | 1796 | Non-Final OA | Oct 11, 2022 |
| 17895312 | ANTI-PSMA RADIOCONJUGATES AND USES THEREOF | CANELLA, KAREN A | 1643 | Final Rejection | Aug 25, 2022 |
| 17835671 | NUCLEIC ACID CONSTRUCTS ENCODING KALLIKREIN-2 FUSION PROTEIN AND VECTORS, PREPARATIONS OF CELLS, AND METHODS OF USE THEREOF | MEYERING, SHABANA SHABBEER | 1635 | Final Rejection | Jun 08, 2022 |
| 17825244 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES | GUSTILO, ESTELLA M | 1646 | Non-Final OA | May 26, 2022 |
| 17752892 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROSTATE CANCER | SKOKO III, JOHN JOSEPH | 1643 | Final Rejection | May 25, 2022 |
| 17767263 | MATERIALS AND METHODS FOR MASS SPECTROMETRIC PROTEIN ANALYSIS | SIMMONS, VALERIE MICHELLE | 1758 | Final Rejection | Apr 07, 2022 |
| 17691277 | Methods for Predicting Treatment Response in Ulcerative Colitis | KENNEDY, SARAH JANE | 1682 | Non-Final OA | Mar 10, 2022 |
| 17691182 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | GEORGE, DENNIS CHERIAN | 1644 | Non-Final OA | Mar 10, 2022 |
| 17691050 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | ALSOMAIRY, SARAH ABDOALATIF | 1646 | Final Rejection | Mar 09, 2022 |
| 17674397 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | SKOKO III, JOHN JOSEPH | 1643 | Final Rejection | Feb 17, 2022 |
| 17633993 | OPTIMIZED CULTURE MEDIA FOR CLOSTRIDIA BACTERIA | DICKENS, AMELIA NICOLE | 1645 | Non-Final OA | Feb 09, 2022 |
| 17615949 | ANTI-TNF ANTIBODY COMPOSITIONS, AND METHODS FOR THE TREATMENT OF PSORIATIC ARTHRITIS | DAHLE, CHUN WU | 1641 | Final Rejection | Dec 02, 2021 |
| 17615959 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | XIE, XIAOZHEN | 1674 | Final Rejection | Dec 02, 2021 |
| 17524516 | Methods of Treating Multiple Myeloma with an Anti-CD38 Antibody, Bortezomib, Melphalan and Prednisone | HOWARD, ZACHARY C | 1674 | Final Rejection | Nov 11, 2021 |
| 17240609 | Materials and Methods for Treating Juvenile Idiopathic Arthritis | HOLTZMAN, KATHERINE ANN | 1646 | Final Rejection | Apr 26, 2021 |
| 17182429 | CAPACITY OPTIMIZATION ACROSS DISTRIBUTED MANUFACTURING SYSTEMS | LEE, PO HAN | 3623 | Non-Final OA | Feb 23, 2021 |
| 17174590 | NEOANTIGENS EXPRESSED IN MULTIPLE MYELOMA AND THEIR USES | EDGINGTONGIORDANO, FRANCESCA | 1643 | Non-Final OA | Feb 12, 2021 |
| 17005858 | B-CELL MATURATION COMPLEX CAR T CONSTRUCT AND PRIMERS | HANEY, AMANDA MARIE | 1682 | Non-Final OA | Aug 28, 2020 |
| 16797301 | Methods of Treating Newly Diagnosed Multiple Myeloma with a Combination of An Antibody that Specifically Binds CD38, Lenalidomide and Dexamethasone | SANG, HONG | 1646 | Final Rejection | Feb 21, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial